FRACTYL HEALTH, INC. COMMON STOCK

NASDAQ: GUTS (Fractyl Health, Inc.)

Last update: 23 Jun, 5:44PM

1.61

-0.53 (-24.77%)

  • 1D -24.77%
  • 5D -7.47%
  • 1M -25.81%
  • 6M -17.44%
  • YTD -24.41%
  • 1Y -64.85%
  • 5Y -87.47%
Previous Close 2.14
Open 1.75
Volume 6,190,853
Avg. Volume (3M) 302,703
Market Cap 78,852,328
Price / Sales 1.33
Price / Book 12.68
52 Weeks Range
0.873 (-45%) — 5.00 (210%)
Earnings Date 13 Aug 2025
Operating Margin (TTM) -161,246.67%
Diluted EPS (TTM) -1.94
Quarterly Revenue Growth (YOY) -57.10%
Total Debt/Equity (MRQ) 963.53%
Current Ratio (MRQ) 2.50
Operating Cash Flow (TTM) -78.89 M
Levered Free Cash Flow (TTM) -47.87 M
Return on Assets (TTM) -49.05%
Return on Equity (TTM) -196.81%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock Fractyl Health, Inc. Bullish Bearish

AIStockmoo Score

0.0
Analyst Consensus 3.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 1.0
Technical Oscillators -2.5
Average 0.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
GUTS 79 M - - 12.68
LEGN 7 B - - 7.75
MTSR 3 B - - 6.12
MAZE 504 M - 164.29 1.82
SEPN 483 M - - 1.21
RAPP 439 M - - 1.54

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Sector Healthcare
Industry Biotechnology
% Held by Insiders 4.84%
% Held by Institutions 82.44%

Ownership

Name Date Shares Held
Deer Management Co. Llc 31 Mar 2025 4,770,901
Hcc Manager Llc 31 Mar 2025 4,673,871
52 Weeks Range
0.873 (-45%) — 5.00 (210%)
Median 12.00 (645.34%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
Canaccord Genuity 15 Apr 2025 12.00 (645.34%) Buy 1.15

No data within this time range.

  • 3M
Date Type Details
23 Jun 2025 Announcement Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
23 Jun 2025 Announcement Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
18 Jun 2025 Announcement Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
13 Jun 2025 Announcement Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
04 Jun 2025 Announcement Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
19 May 2025 Announcement Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
17 May 2025 Announcement Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
13 May 2025 Announcement Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
06 May 2025 Announcement Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference
28 Apr 2025 Announcement Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria